Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5VE7C
|
|||
| Drug Name |
SAR442085
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Plasma cell myeloma [ICD-11: 2A83.1; ICD-10: C90.0] | Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04000282) First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sanofi. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.